5-Amino-1MQ

Summary

5-Amino-1MQ is worth a brief partly to correct a common misunderstanding: it isn't a peptide at all. It is a small-molecule drug — an inhibitor of an enzyme called NNMT (nicotinamide N-methyltransferase) — that happens to be sold through the same "research chemical" channels as peptides, and so gets grouped with them. The scientific rationale is real and interesting: NNMT is overactive in obese fat tissue, where it burns through the cell's methyl groups and depletes NAD+ (a coenzyme central to metabolism and a longevity research target). Block NNMT, the theory goes, and you restore NAD+ and reduce fat storage — which is exactly what happens in mice. But that is the entire evidence base for its marketed use: mouse studies. There is no published human efficacy or safety data, which makes the confident "fat-loss compound" marketing especially far ahead of the facts.

What people use it for

5-Amino-1MQ is marketed and used almost entirely for fat loss and body recomposition, and secondarily for metabolic health, "NAD+ boosting," and anti-aging — riding the broader popularity of NAD+ as a longevity target. The pitch is that it removes a "brake" on fat metabolism (NNMT) and raises NAD+, so fat cells store less and burn more. The evidence sections weigh that pitch against a literature that, for human purposes, essentially does not exist yet.

Human evidence

This section is short because the honest answer is stark: there is no published human evidence for 5-Amino-1MQ — none for efficacy, and none for safety. No randomized trials, no controlled studies, not even published human case series demonstrating fat loss or metabolic benefit. Every therapeutic claim made for it is an extrapolation from mouse data. That is why both the human fat-loss claim and the "has established human safety/efficacy" claim grade C: not because the idea has been disproven, but because for humans it is entirely unproven — and selling an unproven research chemical as a working fat-loss compound is the definition of running ahead of the evidence.

Animal / preclinical evidence

The preclinical case is genuine and is the only real evidence here. NNMT (nicotinamide N-methyltransferase) methylates nicotinamide, consuming S-adenosylmethionine (SAM) and contributing to NAD+ depletion; NNMT is overexpressed in the fat tissue of obese animals and humans and is associated with metabolic dysfunction. In the key study (Neelakantan et al., Biochemical Pharmacology, 2018), membrane-permeable small-molecule NNMT inhibitors of this class, given to diet-induced obese mice, reduced body weight, white-fat mass, and adipocyte size, lowered cholesterol, raised intracellular NAD+, and suppressed fat-cell lipogenesis — without reducing food intake and without obvious adverse effects in that model. This is a clean, plausible mechanism with supportive animal results. But "reverses obesity in mice on a high-fat diet" is a starting point for drug development, not evidence of a human effect — and the gap between mouse metabolic studies and human outcomes is wide and frequently fatal to candidate compounds.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Some users of 5-Amino-1MQ report modest fat loss, reduced appetite, or more energy, generally while also dieting and training. With zero human trials, no established dosing, and gray-market product of unknown identity and purity, these reports are especially low-confidence — they can't distinguish any real effect of the compound from diet, expectancy, or placebo, and they provide no information about safety. They are anecdotes about an unproven research chemical, and should be read as such.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

All published dosing for 5-Amino-1MQ and related NNMT inhibitors comes from mouse studies and is expressed per kilogram of body weight in animals — figures that do not translate to humans and provide no basis for human use. There is no human dosing data, so this brief lists no study-dose entries. The amounts circulated in online "protocols" are not study-derived human doses and are not reproduced here.

Safety & side effects

There is no published human safety data for 5-Amino-1MQ. In the mouse studies, NNMT inhibition was reported without obvious adverse effects, but rodent safety over weeks is not human safety, and several specific unknowns matter: NNMT and the NAD+/SAM methylation system it sits in are involved in many tissues, and the consequences of inhibiting NNMT long-term in humans — including any effects on methylation-dependent processes — have not been studied. Because it is sold as an unregulated research chemical, the actual product is also of unverified identity, purity, and dose, adding contamination and mislabeling risk on top of an already-uncharacterized compound. The only honest safety statement is that its safety in humans is unknown.

Regulatory / legal status

5-Amino-1MQ is not FDA-approved, is not approved by any regulator, and is neither an approved drug nor a recognized dietary supplement. It is a small-molecule research chemical (an NNMT inhibitor) — not a peptide, despite being marketed alongside peptides — with an entirely preclinical evidence base and no legitimate clinical or compounding pathway for human use. It is sold online as "research only" / gray-market material. Status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

5-Amino-1MQ shows up in fat-loss, NAD+, and longevity content as a novel "NNMT inhibitor" that melts fat by unlocking your metabolism and boosting NAD+. Two corrections keep this honest. First, it is frequently lumped in with peptides; it is a small molecule, a different kind of compound. Second, and more important, the confident framing as a working fat-loss aid rests on mouse studies only — there is no human efficacy or safety evidence at all. The underlying NNMT/NAD+ biology is a legitimate and active area of metabolic research, which is what gives the marketing its scientific veneer; but an interesting target in mice is not a proven product for people. Where coverage presents 5-Amino-1MQ as an early-stage, preclinical research compound, it squares with the record; where it implies a safe, effective human fat-loss tool, it badly overstates a literature that contains no human data. The critique is of the framing, not of the underlying enzyme science.